ArticleDiscover oncology2025
Inhibition of FXa could be a novel therapeutic target associated with hypoxia-associated tumor behavior?
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundFactor Xa (FXa) plays a role in promoting cancer growth and metastasis via protease-activated receptors. The main aim of this study was to investigate the effect of FXa inhibition, which is known to play a crucial role in cancer metabolism in hypoxia, on the behaviour of colorectal cancer cell lines HCT116 and HT29 using FXa inhibitor-rivaroxaban.
methodsThe studies were conducted under both normoxic and hypoxic conditions. The immunofluorescence method was used to assess the expression of key elements in tumor metabolism, including HIF1 alpha, LDHA, and GLUT1, following the administration of Rivaroxaban, which does not affect cell viability.
resultsHypoxia resulted in increased expression of HIF1 alpha and LDHA. However, it was observed that the expression levels decreased in the rivaroxaban-treated group. It is noteworthy that no statistically significant difference was observed in GLUT1 expression. Moreover, the analysis of E-cadherin and N-cadherin expression levels revealed that Rivaroxaban significantly impacted migration under hypoxic comparison to the control group. These findings were further corroborated by the statistical results of the wound patency in the wound healing experiment. The results reveal that the inhibition of FXa with Rivaroxaban may represent a novel target for the treatment of tumor hypoxia.
conclusionsThe findings of this study suggest that Rivaroxaban has the potential to be both an effective anticoagulant and an anticancer agent against CRC under both hypoxic and normoxic conditions. This paper puts forward an alternative utilization method for Rivaroxaban.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.